You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

http://dx.doi.org/10.1136/rmdopen-2021-002012corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Fleischmann R, Mysler E, Bessette L, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 2022;8:e002012. doi: 10.1136/rmdopen-2021-002012

    Under the Efficacy heading, the sentence ‘Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from adalimumab to upadacitinib were also observed’ has been changed to ‘Numerically higher responses for patients who switched from adalimumab to upadacitinib vs those who switched from upadacitinib to adalimumab were also observed’.